The 10th Annual Biologics Manufacturing Asia 2023 is Asia’s bioprocessing-focused, knowledge-sharing conference that provides regional biopharmaceutical industry stakeholders a carefully tailored networking platform for leveraging opportunities for strategic collaboration, and exposure to the latest manufacturing technologies and know-how. We have an agenda built around success stories from Asia’s biopharmas as well as the technical expertise from International Biopharmas and BIG Pharmas, presentations on the latest manufacturing technologies such as single-use and end-to-end continuous processing for biologics, today’s challenges and opportunities in biomanufacturing, advances in upstream process development, cost-optimization strategies in downstream processing, analytical characterization strategies, facility design, and scale-up strategy, fill & finish innovation to streamline the operations amongst other crucial themes.
Along with the Asia Biologics Festival, the BMA 2023 is co-located with 2nd Aseptic Fill Finish and Packaging, 7th Annual Biologistics World Asia conference, and the iconic in-person Asia-Pacific Bioprocessing Excellence Awards 2023.
Steve CL Lin
Andre Choo PhD
Kai Yin Po
Wei Kuang Chi
We have an agenda built around success stories from Asia’s biopharmas as well as technical expertise from international biopharmas and Big Pharmas, presentations on the latest manufacturing technologies such as single use and continuous processing for biologics, key challenges in cell therapy manufacturing, cost-reduction strategies in downstream processing, sustainability case studies surrounding single use systems, discussions on vaccine manufacturing, know-how on the developments in pathogen safety amongst other crucial themes.
The 10th Annual Biologics Manufacturing World Asia is the largest and the ONLY bioprocess business and technology convention in Asia Pacific! In 2023, 1000+ biomanufacturing stakeholders from Big Pharmas, Biopharmas, Contract Manufacturing Organisations, Academic & Research Institutes, Regulatory Authorities, Solution Providers across Singapore, China, South Korea, Taiwan, Japan, Australia, India, and SouthEast Asia, will convene hybridly to discover, discuss and debate about biologics manufacturing processes, best practices and latest developments to manufacture biologic drugs cheaper and faster!
Explore the most comprehensive upstream processing from early cell isolation and cultivation, cell line engineering, media development, raw materials considerations and more for enhancing and optimizing cell culture return and production rate with cost-reduction strategy. Know-how on the latest development of upstream processing technologies have evolved and potentially changed the biologics drug manufacturing process to be more economically feasible.
Immerse into the most focused biologics downstream processing with the ultimate goal of meeting quality and purity requirements of biologics drug products. Multiple purification approaches, concentration, product recovery, cost reduction and optimizing the integration of continuous manufacturing and utilization of single use disposable systems to optimize biologics manufacturing process production rate will be discussed.
Analytics & Quality
Innovative strategy of assay optimization, real time monitoring system with highest compromisation to quality control of biologics products to a direction of improving efficiency while advocating process automation are the keys to quicker market commercialization and regulatory compliance. Topics built around cost and process optimization with latest developments in analytics and quality to foster biologics enhancement.
Facility Design, Tech-Transfer & Scale-Up Strategy
Understand the challenges and the trends of biomanufacturing facility design in detail and find out the best practices of formulation and bulk technology transfer for optimizing output while maintaining quality and activity of products. Emphasis on scaling up processes without compromising product quality while discussing the latest technology and solution to scale up for maximum output.
Emerging Technologies and Applications
Identify the most imminent trends on the emerging technologies and applications with the potential to enhance and fasten the biologics manufacturing process. Applications such as PAT tools, novel technologies in single-use technologies and continuous processing, as well as automation and bioprocessing 4.0 to fasten the biologics manufacturing process will be discussed.
This year at the APAC regions biggest and only biologics focused conference, we are glad to introduce the first ever CMO Pavilion only at the 10th Annual Biologics Manufacturing Asia 2023, 15-16 March 2023 at Sands Expo & Convention Center, Marina Bay Sands, Singapore.
CMOs from over 10 countries in the APAC region will represent & showcase innovative development and manufacturing services and technologies to the largest gathering of 300+ biologics development companies only at the 10th Annual Biologics Manufacturing Asia 2023.
The Asia-Pacific Bioprocessing Excellence Awards 2023 (ABEA) seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost, and superior quality.
Featuring top bioprocessing and biomanufacturing leaders in the industry, along with the latest advances in technologies and best practices in manufacturing, the Asia-Pacific Bioprocessing Excellence Awards applauds extraordinary leaders & trend-setters of today and inspires innovators of tomorrow.
- Best Bioprocessing Supplier Award: Upstream Processing
- Best Bioprocessing Supplier Award: Downstream Processing
- Best Bioprocessing Supplier Award: Fill-Finish
- Best Bioprocessing Supplier Award: Automation - Software
- Best Bioprocessing Supplier Award: Automation - Hardware
and many many more!
MasterControl Inc. is the leading provider of cloud-based quality and compliance software for life sciences and other regulated industries. Our mission is the same as that of our customers – to bring life-changing products to more people sooner.
You can use the MasterControl Product Lifecycle Excellence™ platform to digitize, automate and connect quality and compliance processes at every step – from concept to commercialization. Join over 1,000 companies worldwide that rely on MasterControl solutions to achieve new levels of operational excellence across product development, clinical trials, regulatory affairs, quality management, supply chain, manufacturing and postmarket surveillance.
Learn more at www.mastercontrol.com
Pall Corporation provides critical filtration, separation, and purification solutions to meet the demanding needs of a broad spectrum of life sciences and industrial customers around the globe. Across 80 locations and 10,000 people worldwide, we are unified by a singular drive: to solve our customers' biggest fluid management challenges. And in doing so advance health, safety, and environmentally responsible technologies. Together, our Life Sciences and Industrial teams serve a diverse range of customers including biotechnology, pharmaceutical, medical, food and beverage, laboratory, microelectronics, aerospace, fuels, petrochemical, chemical, automotive and power generation industries. Our industry-leading technologies and solutions are at work in countless applications, protecting critical operating assets, improving product quality, safeguarding the health, and minimizing emissions and waste
For more info, please check: https://www.pall.com/en/biotech.html
Cytiva is a global life sciences leader with more than 8,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture, and delivery of transformative medicines to patients.
Ajinomoto Genexine is providing customers with the CELLiST™ series developed based on Ajinomoto's media manufacturing technology and know-how,
which has been researching serum-free media for over 30 years, through a number of domestic and overseas agencies. https://en.ajinomotogenexine.
AGC Biologics is a global CDMO with seven facilities worldwide providing process development and manufacturing services for protein-based biologics and advanced therapies. From development to clinical trials, to full-scale commercialization, we can help you reach your goals at any stage in the development or manufacturing process. We specialize in the following modalities and substances, mammalian and microbial-based therapeutic proteins, recombinant DNA, plasmid DNA (pDNA), viral vectors, messenger RNA (mRNA), and genetically engineered cells. Our services range from Process Development, Analytical Development, cGMP Manufacturing (both clinical and commercial), Quality Control, and Quality Assurance and Process Validation.
GenScript ProBio is the subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine, biologics discovery and antibody protein drug to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Merck, a life science leader, is a business of Merck KGaA, Darmstadt, Germany. Our products and services help you safely and efficiently develop and manufacture therapeutics.
Our BioReliance® Biosafety Testing Services offer comprehensive and integrated services that support every phase of the testing, development and manufacturing process.
Your Therapy, Our Priority
Visit our Merck booth.
Speak to us, and learn more:
Science and Lab Solutions (SLS) provides a more seamless experience to customers as they continue to benefit from our scientific expertise and access to one of the broadest portfolios in the industry.
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics from concept to commercialization for the benefit of patients worldwide.
With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2022, WuXi Biologics is supporting 534 integrated client projects, including 14 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
- The 3M biopharmaceutical business is a subset of the 3M Separation and Purification Sciences Division which utilizes cutting edge 3M material science that pushes the boundaries of purification, filtration, and separation to support production, processes that change lives, and deliver quality solutions where it matters most.
- Our biopharma and materials science expertise can help you improve in-process purity, increase the yield of your product and lower manufacturing costs – so you can focus on bringing life-saving treatments to trial and market
- Biopharmaceutical Purification | 3M
Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry. https://www.lonza.com/
EuBiologics is developing new vaccine products with the goal of distributing safe and effective vaccines that can contribute to the promotion of global public health. In addition, it is a specialized bio company that provides CRMO (Contract Research and Manufacturing Organization) services for various biopharmaceuticals based on advanced facilities suitable for biopharmaceutical research and production, professional manpower, and rich experience in the field. Starting with Euvichol-Plus, which occupies more than 80% of the global cholera vaccine market, EuBiologics is developing new infectious disease preventive vaccines using EuIMT using the immune enhancer EcML and EuVCT technology using the recombinant protein rCRM197.
We have a cGMP-level plant (C Plant & V Plant), and we provide customized CRMO services in consideration of improving product quality and securing competitiveness for the entire production cycle of biopharmaceuticals derived from mammalian cells and microorganisms, from cell line development to GMP production.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
For more information, please visit www.thermofisher.com
Since 1998, Ami Polymer is in the business of Silicone Elastomeric products and also, other Polymeric components which ultimately provide solutions to Fluid Transfers, Sealing, and Contamination controls for Biopharma, Pharma, Medical, Laboratory, Food, Beverages, and Engineering sectors worldwide. We Are Experts in Silicone Tubing, Hoses & Single-Use Assemblies.
Ami Polymer is having ISO Class VII and ISO Class VIII Cleanroom facilities certified with ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, ISO 27001:2013, ISO 13485:2016. We also have a BPOG extractables program for our products for regulatory markets worldwide.
Aptamer Group develops custom affinity binders for use across the life sciences using its proprietary Optimer® platform. Optimer binders can be used as antibody alternatives to offer novel or improved solutions in downstream affinity purification and QC assays to support product release. Optimer binders are removing the barriers to innovation in the life sciences by offering simple resin compatibility, tuneable binding kinetics and high stability. https://aptamergroup.com/
Eppendorf – Stimulating growth. Cultivating Solutions Efficient bioprocesses are central to the production of biopharmaceuticals, biomass, chemical building blocks, and nutritional products. Scientists from industry and academia trust Eppendorf bioprocess solutions for the cultivation of mammalian, insect, plant, and stem cells, as well as bacteria, yeasts, and fungi. Scalable systems support the upstream bioprocessing cycle from early development to scale-up to pilot-scale production, in working volumes from 65 mL to 2,400 L. Powerful hardware and software tools for process monitoring, control, and analytics, help to build process understanding and facilitate standardized process control. By utilizing the strong synergies between bioreactor technology and polymer manufacturing, Eppendorf developed a wide selection of single-use bioreactors and fermentors which complement its portfolio of glass and stainless-steel vessels. With worldwide technical and application services, clear technical documentation, and preventive maintenance services, Eppendorf ensures reliable system operation. Since 1945, the Eppendorf brand has been synonymous with customer-oriented processes and innovative products, such as laboratory devices and consumables for liquid handling, cell handling and sample handling. Today, Eppendorf and its more than 5000 employees serve as experts and advisors, using their unique knowledge and experience to support laboratories and research institutions around the world.
Pfanstiehl is the market leader of high purity, low endotoxin, low metal excipients for biologics, biosimilars, vaccines, cell culture media and injectable (liquid and lyophilized) formulations and supplies its products to nearly all leading global biopharmaceutical companies.
Pfanstiehl was founded in 1919 and currently celebrating its 103rd anniversary year in 2022. Pfanstiehl is headquartered at Waukegan, IL, USA and has diverse global technical support team across the globe in USA, Europe & APAC.
Pfanstiehl has manufactured parenteral grade excipients for more than 50 years, and Pfanstiehl’s high purity, low endotoxin and low metal excipient products are known as “best in class” due to their high characterization, performance, consistency, and quality attributes.
Pfanstiehl’s excipients are critical components in the majority of the global blockbuster biopharmaceutical drugs and vaccines including majority of the Covid -19 vaccines that were administered globally.
Terumo Pharmaceutical Solutions develops patient-oriented parenteral delivery solutions for therapeutic performance and safety Globally trusted for quality and precision, Terumo Pharmaceutical Solutions offers pharmaceutical and medical device manufacturers around the world comprehensive product design and development services, for primary container, injection, infusion therapy devices, and contract development and manufacturing services (CDMO).
We have decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to product commercialization to optimize critical aspects of parenteral
drug delivery. Innovation and creativity are central to our value proposition. Our expert teams lead the industry in developing and manufacturing advanced, high-performing infusion and injection technologies for
all parenteral applications. We provide sterile injectable contract development and manufacturing (CDMO) services from initial combination device design and formulation development to commercial manufacturing.
supporting better patient outcomes around the world.
We listen. We question. We deliver.
Emerson is where technology and engineering come together to create solutions for the benefit of our customers, driven without compromise for a world in action. As a global innovator, Emerson has a deep legacy of solving the most complex challenges facing modern life. We combine advanced technologies, industry-leading expertise and an insatiable curiosity about the world around us to create sustainable solutions for the essential customers we serve.
Our how is complex, but our why is simple and found in our unified global Purpose: We drive innovation that makes the world healthier, safer, smarter and more sustainable. https://www.emerson.com/en-sg/
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organization, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry.
For ongoing news, visit www.a-star.edu.sg.
Cold Chain Platform (CCP) is 100% focused on cold chain and logistics in the biopharmaceutical, life science, and healthcare industries. CCP services help global companies reach the right partners and get a firm foothold in the Asia Pacific. CCP works with global organizations to help them gain access to the APAC cold chain, logistics, and pharmaceutical market through a highly targeted audience.
BioPharma Asia aims to keep its readers abreast of all developments in the areas of Manufacturing, Development, Quality Assurance, Outsourcing, and Regulatory Affairs, with only the highest quality articles and webinars written and presented by the most respected authors/presenters, associated with only end-user companies. This ensures that the information will always be guaranteed to remain timely, informative and above all totally unbiased.
Present your expertise to the Asian Bioprocessing industry’s key stakeholders through a variety of available speaking packages.
Join the exhibition, and build an impressive presence among your potential clients.
Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.
Engage with and build lasting connections that matter the most to your business.
Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.